Erika Hamilton: KN522 OS data shows 5% overall survival improvement in TNBC with pembrolizumab

Erika Hamilton posted the following on Twitter:

“KN522 OS data 5 years after the initial pCR presentation. 75 months of follow-up for chemo +/- pembrolizumab in stage II and III TNBC.

• Event-free survival is stable from before with 9% improvement with pembrolizumab.
• Overall survival improved by 5% (81.7% -> 86.6%).”

Source: Erika Hamilton/X

Erika Hamilton is a medical oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute (USA). Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee.

She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.